Es reseña de:
Modifiable risk factors, cardiovascular disease, and mortality in 155 722 individuals from 21 high-income, middle-income, and low-income countries (PURE): a prospective cohort study
Perry Hystad
The Lancet, Vol. 395, Núm. 10226, 2019
Vericiguat in Patients with Heart Failure and Reduced Ejection Fraction
Paul W. Armstrong, Burkert Pieske, Kevin J. Anstrom, Justin Ezekowitz, Adrian F. Hernandez, Javed Butler
The New England Journal of Medicine, Vol. 382, Núm. 20, 2020
Predicting Benefit From Evolocumab Therapy in Patients With Atherosclerotic Disease Using a Genetic Risk Score: Results From the FOURIER Trial
Nicholas A. Marston, Frederick K. Kamanu, Francesco Nordio, , Yared Gurmu, Carolina Roselli, Peter S. Sever
Circulation, Vol. 141, 2020
Predictive Accuracy of a Polygenic Risk Score Compared With a Clinical Risk Score for Incident Coronary Heart Disease
J. D. Mosley, D. K. Gupta, J. Tan, J. Yao, Q. S. Wells, C. M. Shaffer
JAMA, Vol. 323, Núm. 7, 2020
© 2001-2024 Fundación Dialnet · Todos los derechos reservados